Product News

Seegene's product news

Obtained CE-IVD marking for Allplex™ MG & AziR Assay

Sexually Transmitted Infections Allplex™ MG & AziR Assay 2018.10.29

Seegene has received CE-IVD mark under European Union on In Vitro Diagnostics Medical Devices for Allplex™ MG & AziR Assay.

This assays is a multiplex real-time PCR assay that detects and identifies Mycoplasma genitalium (MG) and 6 mutations causing azithromycin resistance. Azithromycin is generally prescribed for 1st-line treatment of MG. Based on Seegene’s proprietary DPO™ & MuDT™ Technology, this assay enables to check MG infection and azithromycin resistance in a single test and reports multiple Ct values of each pathogen in a single tube.

Previous Next List
Previous Obtained CE-IVD marking for Allplex™ GI-Virus plus Assay 2019.01.22
Next Obtained CE-IVD marking for assays that detects MTB and Multi-Drug Resistance and Extensively Drug Resistance 2019.01.22
home > News > Product news